REMARKS

The present Amendment is in response to the Office Action dated

January 22, 2004 in reference to the above-identified application. The

Examiner set a shortened statutory period for reply of three (3) months,

making the present Amendment due by April 22, 2004. Filed concurrently

herewith is a request for a one-month extension of time so that the present

Amendment is due by May 22, 2004, which is a Saturday so that the present

Amendment is due by Monday, May 24, 2004.

Also filed with the present Amendment is a Request for Continued

Examination (RCE) Transmittal, PTO form PTO/SB/30, and check no. 18330

in the amount of \$385.00 as required by 37 C.F.R. 1.114 and 37 C.F.R.

1.17(e). The Commissioner is hereby authorized to charge any deficiency in

the payment of the required fee(s) or credit any overpayment to Deposit

Account No. 13-1940.

In the final Office Action, claims 1-12 and 23-27 were pending with

claims 28-37 withdrawn from further consideration. Claims 1-12 and 23-27

were rejected under 35 U.S.C. § 112, second paragraph, "as being indefinite

for failing to particularly point out and distinctly claim the subject matter which

applicant regards as the invention. Claims 1-12 and 23-27 were rejected

under 35 U.S.C. § 102(b) and 35 U.S.C. § 103(a) as being anticipated by or

as or otherwise obvious in view of U.S. Patent No. 4,943,433 to Rudov,

Publication No. WO91/11191, or AU A 81985/87.

To address the rejections, Applicant has canceled claims 1-12 and 23-

27 and has added new claims 38-64, which are directed to a pharmaceutical

RCE Submission – Amendment Ser No. 10/088 954 composition. Generally, the new independent claims recite that the

pharmaceutical composition comprises a primary substance adapted to

provide a primary chemical treatment, a pharmaceutically acceptable liquid

extract from a juice derived from cereal plants to reduce the incidence or

severity of side effects associated with the primary substance, and a

pharmaceutically acceptable carrier. Applicant submits that the references

made of record neither anticipate nor render obvious the new claims

presented because the references do not teach a composition comprised of

all three elements. Rather, at best, the references teach compositions that

comprise two of the elements - the liquid extract and a pharmaceutically

acceptable carrier therefor.

As explained in the response to the previous office action, both U.S.

Patent No. 4,943,433 and AU-A-81985/87 relate to a pharmacologically

effective or cosmetic substance for external application to treat e.g. acne,

pimples, ulcers, cold sores. The substance includes an extract from plants of

the grass family of plants particularly cereals, that is carried in a

pharmaceutically acceptable aqueous carrier or excipient. The reference

does not teach nor suggest the addition of a "primary substance" for the

treatment of these ailments because the extract is effectively the "primary

substance" of the composition disclosed.

With respect to Publication No. WO91/11191, the reference relates to a

pharmacologically effective composition for direct introduction into body

tissues or vessels for the treatment, for example, of tumors and viral

infections. The composition includes the extract derived from cereal plants

RCE Submission – Amendment Ser. No. 10/088,954

and a pharmacologically acceptable liquid carrier. As with the other two

references made of record, Publication No. WO91/11191 does not teach nor

suggest the addition of a "primary substance" to the composition because the

extract is effectively the "primary substance" used for the treatment of the

ailments.

The combination of a primary treatment substance, such as an

antibiotic, administered simultaneously along with the plant extract in a

common carrier, is not disclosed or suggested in the cited prior art. The

composition disclosed and claimed provides a novel, effective, and efficient

therapeutic treatment for animals that has not previously been recognized,

noted, or observed, and that is not taught or suggested by the references of

record.

Based on the foregoing, Applicant submits that the present application

is in complete condition for allowance, and action to that end is courteously

solicited. If any issues remain to be resolved prior to the granting of this

application, the Examiner is requested to contact the undersigned attorney for

the Applicant at the telephone number listed below.

RCE Submission – Amendment Ser. No. 10/088,954

No additional claims fees are believed to be payable upon the Amendment. However, the Commissioner is hereby authorized to charge any deficiency in the required fees, or to credit any overpayment, to deposit account number 13-1940.

Respectfully submitted,

TIMOTHY J. MARTIN, P.C.

By: Killiam 128,640
Timothy J. Martin, #28,640
Michael R. Henson, #39,222
Rebecca A. Gegick, #51,724
9250 West 5th Avenue, Suite 200
Lakewood, Colorado 80226
(303) 232-3388

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8

I hereby certify that the foregoing **AMENDMENT** (11 pages), and **Request for a one--month Extension of Time** (2 pages) is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450on this day of May, 2004.

Rebecca A. Gegick